Insider Selling: Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Sells 37,070 Shares of Stock

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Nancy A. Simonian sold 37,070 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $0.27, for a total transaction of $10,008.90. Following the transaction, the director now owns 4,000 shares of the company’s stock, valued at $1,080. This represents a 90.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Syros Pharmaceuticals Price Performance

Shares of SYRS stock traded down $0.00 during trading hours on Wednesday, hitting $0.25. 2,212,068 shares of the company’s stock were exchanged, compared to its average volume of 2,376,630. Syros Pharmaceuticals, Inc. has a fifty-two week low of $0.18 and a fifty-two week high of $8.17. The firm has a market cap of $6.62 million, a P/E ratio of -0.08 and a beta of 1.33. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. The firm has a 50 day moving average of $1.62 and a two-hundred day moving average of $3.31.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter in the previous year, the company earned ($1.35) EPS. Sell-side analysts forecast that Syros Pharmaceuticals, Inc. will post -2.94 EPS for the current year.

Institutional Investors Weigh In On Syros Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in shares of Syros Pharmaceuticals during the first quarter valued at approximately $64,000. GSA Capital Partners LLP acquired a new position in Syros Pharmaceuticals in the 3rd quarter valued at $34,000. Certuity LLC acquired a new position in Syros Pharmaceuticals in the 2nd quarter valued at $109,000. Acadian Asset Management LLC lifted its holdings in Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Syros Pharmaceuticals by 21.3% during the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after purchasing an additional 163,234 shares during the last quarter. 91.47% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SYRS. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. StockNews.com initiated coverage on Syros Pharmaceuticals in a research report on Friday, November 29th. They issued a “sell” rating on the stock. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Piper Sandler reissued an “overweight” rating and set a $5.00 price target (down from $13.00) on shares of Syros Pharmaceuticals in a report on Tuesday, August 13th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $3.33.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.